Trial Profile

A randomized phase II trial to evaluate the combination of ONCOS-102, Keytruda (pembrolizumab), MSD's anti-PD-1 therapy, and standard of care (SoC) chemotherapy in first line malignant pleural mesothelioma

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 30 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Jun 2020 New trial record
24 Jun 2020 According to a Targovax media release, there is strong interest to participate in the trial among key opinion leaders and investigators, and multiple centers in both the USA and EU will be participating. The aim is to start enrolling patients into the trial within twelve months.
24 Jun 2020 According to a Targovax media release, company has entered into a collaborative agreement with Merck & Co with the intent to initiate this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com